Analysis of brain tumor tissue from 45 patients found increased CB1 receptor expression in tumor tissue and significantly higher CB2 receptor expression in blood vessels of grade III and IV astrocytomas compared to grade II and controls.
Neuro-oncologists, cancer researchers studying cannabinoid receptors, and those interested in targeted tumor therapies.
CB2 in blood vessels significantly higher in grade III-IV tumors
What the researchers found
CB1 receptor expression was increased in tumor tissue across grades. CB2 receptor expression in blood vessels was significantly higher in grade III (anaplastic astrocytoma) and grade IV (glioblastoma) compared to grade II and control tissue, suggesting CB2 levels correlate with malignancy.
Why it matters
If cannabinoid receptor expression increases with tumor aggressiveness, these receptors could serve as both diagnostic markers for tumor grade and potential therapeutic targets for cannabinoid-based treatments.
The numbers in context
45 patient tissue samples. CB2 was significantly higher in grade III-IV vs grade II blood vessels. CB1 was increased in tumor tissue overall. Three complementary methods confirmed findings.
How the study worked
Brain tumor tissue from 45 patients was analyzed using immunofluorescence, quantitative RT-PCR, and western blotting to measure CB1 and CB2 receptor expression in tumor tissue and blood vessels across astrocytoma grades.
What this study cannot tell us
Relatively small sample from a single center. The study measured expression levels but did not test whether targeting these receptors affects tumor growth. Correlation between receptor expression and tumor grade does not prove a functional role.
How to read the evidence
Moderate: original tissue analysis with three complementary methods, though limited by sample size and descriptive design.
When this study was published
Published in 2020 in Molecular Biology Reports.
The bigger picture
The CB2 finding in tumor blood vessels is particularly intriguing because high-grade astrocytomas depend on new blood vessel formation (angiogenesis), and CB2 may play a role in this process, making it a potential anti-angiogenic target.
Questions still open
- Could CB2-targeted therapies inhibit tumor angiogenesis in high-grade astrocytomas? Would cannabinoid receptor expression predict treatment response? Do other brain tumor types show similar receptor patterns?
Common questions
Does this mean cannabinoids can treat brain cancer?
Why is CB2 in blood vessels important?
Read the original research
The expression level of cannabinoid receptors type 1 and 2 in the different types of astrocytomas.
Molecular biology reports, 47(7), 5461-5467
Citation
Hashemi, Mansoureh; Bashi, Senada; Zali, Alireza. (2020). The expression level of cannabinoid receptors type 1 and 2 in the different types of astrocytomas.. Molecular biology reports, 47(7), 5461-5467. https://doi.org/10.1007/s11033-020-05636-8
Explore the wider topic
- CBD Oil Quality Guide: How to Avoid Snake Oil
- Anxiety After Quitting Weed: When to Consider Medication
- Cannabis for Chemotherapy Nausea: What the Evidence Actually Shows
- Cannabis for Chronic Pain: What the Research Actually Supports
- Cannabis and Epilepsy: The Epidiolex Story and What It Means
- Does CBD Actually Work for Anxiety? What the Evidence Shows
- Does CBD Help with Weed Withdrawal? What Studies Show
- CBD vs THC: The Differences That Actually Matter
- The Proven Medical Benefits of Cannabis: What Research Supports
- Quitting Weed Before Surgery
- Weed and Medications: What Changes When You Quit
- Quitting Weed During Pregnancy: What You Need to Know
- Quitting Weed While Pregnant: What You Need to Know
- Cannabis and Older Adults: Risks Seniors Should Know
- Cannabis and Breastfeeding: THC in Breast Milk